<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>25(1)</volume><submitter>Zeng A</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Osteosarcoma demonstrates limited responsiveness to PD-1 blockade, largely due to its immunosuppressive tumor microenvironment (TME). The specific mechanisms by which cancer-associated fibroblasts (CAFs) contribute to immunosuppression in osteosarcoma are not fully understood.&lt;h4>Methods&lt;/h4>We performed single-cell RNA sequencing (scRNA-seq) on osteosarcoma tissues from patients treated with neoadjuvant chemotherapy and anti-PD-1 therapy to investigate the tumor microenvironment. Cellular composition, gene expression programs, and signaling pathways were analyzed. Functional assays, pull-down and PLA-flow binding validation, and in vivo mouse models were used to dissect the mechanisms by which CAF-derived factors influence CD8⁺ T cell function and contribute to immunoth</pubmed_abstract><journal>Molecular cancer</journal><pagination>14</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12829093</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma.</pubmed_title><pmcid>PMC12829093</pmcid><pubmed_authors>Wang A</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Song G</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Wu H</pubmed_authors><pubmed_authors>Deng C</pubmed_authors><pubmed_authors>Zeng A</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Tang Q</pubmed_authors><pubmed_authors>Lu J</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Luo T</pubmed_authors><pubmed_authors>Song Y</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma.</name><description>&lt;h4>Background&lt;/h4>Osteosarcoma demonstrates limited responsiveness to PD-1 blockade, largely due to its immunosuppressive tumor microenvironment (TME). The specific mechanisms by which cancer-associated fibroblasts (CAFs) contribute to immunosuppression in osteosarcoma are not fully understood.&lt;h4>Methods&lt;/h4>We performed single-cell RNA sequencing (scRNA-seq) on osteosarcoma tissues from patients treated with neoadjuvant chemotherapy and anti-PD-1 therapy to investigate the tumor microenvironment. Cellular composition, gene expression programs, and signaling pathways were analyzed. Functional assays, pull-down and PLA-flow binding validation, and in vivo mouse models were used to dissect the mechanisms by which CAF-derived factors influence CD8⁺ T cell function and contribute to immunoth</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T21:23:32.804Z</modification><creation>2026-06-05T03:11:51.256Z</creation></dates><accession>S-EPMC12829093</accession><cross_references><pubmed>41413558</pubmed><doi>10.1186/s12943-025-02516-2</doi></cross_references></HashMap>